Clinical Trials Directory

Trials / Completed

CompletedNCT00375570

Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents

An Open Label, Multi-Centre, Phase III, Subject Initiated Safety Study of ME-609 in Treatment of Recurrent Herpes Simplex Labialis in Adolescents

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
254 (actual)
Sponsor
Medivir · Industry
Sex
All
Age
12 Years – 17 Years
Healthy volunteers
Not accepted

Summary

The Purpose of this study is to evaluate the safety of ME-609 for the treatment of recurrent herpes labialis in adolescents.

Detailed description

The objective of the study was to evaluate the safety of ME-609 for the treatment of herpes labialis recurrences in immunocompetent adolescents, 12 - 17 years of age, following a 5-day treatment with 5-time daily topical administration.

Conditions

Interventions

TypeNameDescription
DRUGME-609Topical treatment 5 times daily for 5 days

Timeline

Start date
2006-10-01
Primary completion
2007-09-01
Completion
2007-09-01
First posted
2006-09-13
Last updated
2008-08-18

Source: ClinicalTrials.gov record NCT00375570. Inclusion in this directory is not an endorsement.

Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents (NCT00375570) · Clinical Trials Directory